Although the application of TIM-3 blockade in eye diseases is still in its early stages, a strategic approach that combines TIM-3 and PD-1 inhibition could provide a viable treatment option for both tumors and autoimmune eye disorders.60 Here, HAVCR2 is linked to eye disorder.